Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

Blood (2013) 122 (24): 3951–3959.

https://doi.org/10.1182/blood-2013-05-502773

Published: 2013

Includes: Supplemental data

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Fátima de la Cruz Vicente, Estrella Carrillo Cruz, María Solé Rodríguez, Ana Marín Niebla, Eduardo Ríos Herranz, María Luz Martino Galiana, Jose Falantes González, Isabel Montero Cuadrado, Jose González Campos, Ildefonso Espigado Tocino, Jose A Pérez-Simón

Blood (2013) 122 (21): 5087.

https://doi.org/10.1182/blood.V122.21.5087.5087

Published: 2013

Journal Articles

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

Blood (2013) 122 (21): 509.

https://doi.org/10.1182/blood.V122.21.509.509

Published: 2013

Journal Articles

Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study.

Emmanuel Bachy, MD, John F. Seymour, MBBS FRACP, Pierre Feugier, MD, PhD, Fritz Offner, Dolores Caballero, MD, Reda Bouabdallah, MD, Lars Möller Pedersen, MD, PhD, Pauline Brice, MD, David Belada, M.D., Ph.D., Luc Xerri, MD, PhD, Gilles Salles, MD

Blood (2012) 120 (21): 2649.

https://doi.org/10.1182/blood.V120.21.2649.2649

Published: 2012

Journal Articles

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Pau Abrisqueta, MD, Neus Villamor, MD, PhD, María José Terol, MD, PhD, Eva González-Barca, MD, PhD, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose Antonio García-Marco, MD, PhD, Yolanda González, MD, Felix Carbonell, MD, PhD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, MD, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3930.

https://doi.org/10.1182/blood.V120.21.3930.3930

Published: 2012

Journal Articles

Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma,

Xiaolei Zhou, Jianmin Wang, Jessica Zhang, Catherine Copley-Merriman, Yasuhiro Torigoe, Carolina Reyes, PhD, John F. Seymour, MD, PhD, Armando Lopez-Guillermo, MD, Fritz C. Offner, MD, PhD, Marek Trneny, Gilles Andre Salles

Blood (2011) 118 (21): 3661.

https://doi.org/10.1182/blood.V118.21.3661.3661

Published: 2011

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Francesc Bosch, MD, PhD, Pau Abrisqueta, Neus Villamor, MD. PhD, María José Terol, MD, PhD, Eva González-Barca, MD, Marcos González, MD, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD

Blood (2011) 118 (21): 293.

https://doi.org/10.1182/blood.V118.21.293.293

Published: 2011

Journal Articles

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

Blood (2010) 116 (21): 1788.

https://doi.org/10.1182/blood.V116.21.1788.1788

Published: 2010

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Francesc Bosch, MD, PhD, Neus Villamor, Pau Abrisqueta, MD, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD

Blood (2010) 116 (21): 1382.

https://doi.org/10.1182/blood.V116.21.1382.1382

Published: 2010

Journal Articles

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

Francesc Bosch, MD, PhD, Pau Abrisqueta, MD, Neus Villamor, MD, PhD, Maria Jose Terol, MD, Josep-Maria Ribera, MD, Eva Gonzalez-Barca, MD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Yolanda Gonzalez, MD, Secundino Ferrer, MD, Felix Carbonell, MD, Lourdes Escoda, MD, Isidro Jarque, MD, Encarnacion Monzo, MD, Ana Muntañola, MD, Olga Salamero, MD, Emili Montserrat, MD

Blood (2008) 112 (11): 2097.

https://doi.org/10.1182/blood.V112.11.2097.2097

Published: 2008

Journal Articles

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Francesc Bosch, MD, PhD, Ana Muntañola, MD, Neus Villamor, MD, Maria Jose Terol, MD, Elena Gonzalez-Barca, MD, Josep Maria Ribera, MD, PhD, Marcos Gonzalez, MD, Eugenia Abella, MD, Julio Delgado, MD, Felix Carbonell, MD, PhD, Jose A. Garcia-Marco, MD, PhD, Lourdes Escoda, MD, Secundino Ferrer, MD, E. Monzo, MD, Yolanda Gonzalez, MD, Pau Abrisqueta, MD, Olga Salamero, MD, Eva Gine, MD, Emili Montserrat, MD, PhD

Blood (2007) 110 (11): 626.

https://doi.org/10.1182/blood.V110.11.626.626

Published: 2007

Journal Articles

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, Hans-Peter Böck, Roland Repp, Hannes Wandt, Christiane Pott, John F. Seymour, Bernd Metzner, Annette Hänel, Tanja Lehmann, Frank Hartmann, Hermann Einsele, Wolfgang Hiddemann

Blood (2006) 108 (13): 4003–4008.

https://doi.org/10.1182/blood-2006-04-016725

Published: 2006

Includes: Supplemental data

Journal Articles

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Martin H. Dreyling, MD, Roswitha Forstpointner, MD, Hans-Peter Boeck, MD, Roland Repp, MD, Hannes Wandt, MD, Christiane Pott, MD, John Francis Seymour, MD, Bernd Metzner, MD, Annette Haenel, MD, Tanja Lehmann, MD, Frank Hartmann, MD, Hermann Einsele, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 2769.

https://doi.org/10.1182/blood.V108.11.2769.2769

Published: 2006

Journal Articles

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, PhD, Roswitha Forstpointner, PhD, Martin Dreyling, PhD, Martin Gramatzki, PhD, Hans-Peter Böck, MD, Mathias Hänel, MD, John Seymour, MD, Manfred Planker, MD, Ulrich Dührsen, PhD, Klaus Wilms, PhD, Martin Clemens, PhD, Wolf-Dieter Ludwig, MD, Hannes Wandt, MD, Rita Pasold, MD, Michael Unterhalt, MD

Blood (2005) 106 (11): 920.

https://doi.org/10.1182/blood.V106.11.920.920

Published: 2005

Journal Articles

Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL.

Francesc Bosch, A. Ferrer, N. Villamor, E. Gine, M.A. Abella, S. Gardella, J. Besalduch, M. Gonzalez, A. Altes, L. Escoda, S. Ferrer, E. Gonzalez-Barca, E. Perez-Ceballos, A. Asensi, E. Montserrat

Blood (2005) 106 (11): 718.

https://doi.org/10.1182/blood.V106.11.718.718

Published: 2005

Journal Articles

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Roswitha Forstpointner, Martin Dreyling, Roland Repp, Sandra Hermann, Annette Hänel, Bernd Metzner, Christiane Pott, Frank Hartmann, Frank Rothmann, Robert Rohrberg, Hans-Peter Böck, Hannes Wandt, Michael Unterhalt, Wolfgang Hiddemann

Blood (2004) 104 (10): 3064–3071.

https://doi.org/10.1182/blood-2004-04-1323

Published: 2004

NARROW

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study.

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma,

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM) Is a Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia.

Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only